Email this article OPTIMIZATION OF METASTATIC COLORECTAL CANCER TREATMENT WITH RAS MUTATIONS
- Authors: Bolotina L.V.1
-
Affiliations:
- P.A. Herzen Moscow Oncology Research Institute, Ministry of Health of Russia
- Issue: Vol 2, No 4 (2013)
- Pages: 31-33
- Section: REVIEW
- Published: 01.03.2015
- URL: https://onco-surgery.info/jour/article/view/90
- DOI: https://doi.org/10.17650/2220-3478-2013-0-4-31-33
- ID: 90
Cite item
Full Text
Abstract
Current knowledge concerning impact of certain mutations on targeted therapy efficacy underlines the necessity to perform genetical analysis in order to choose appropriate treatment. Panitumumab addition to 1st line metastatic colorectal cancer chemotherapy in patients with wild-type RAS allows to achieve median progression-free survival up to 13 months and median overall survival of 41,3 months.
Keywords
About the authors
L. V. Bolotina
P.A. Herzen Moscow Oncology Research Institute, Ministry of Health of Russia
Author for correspondence.
Email: lbolotina@yandex.ru
Russian Federation
References
Supplementary files
